澳门特别行政区首次批准内地未上市中药创新药Ⅲ期临床试验：监管比较与实践启示意义
王丹, 李鹏斌, 赵军宁
Macao SAR’s First Authorization of a Phase III Clinical Trial for an Innovative Traditional Chinese Medicine Drug Not Yet Marketed in the Chinese Mainland: Regulatory Comparison and Practical Implications
WANG Dan, LI Peng-bin, ZHAO Jun-ning
中国食品药品监管
.
2026, (10): 4
-17
.
DOI: 10.3969/j.issn.1673-5390.2026.10.001
京公网安备11010802023381号